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   ABSTRACT 
  Objective      The development of non-Hodgkin’s lymphoma 
(NHL) confers a high risk of mortality in primary Sjögren’s 
syndrome (pSS) patients, but the sensitivity and speciﬁ  city 
of proposed lymphoma predictors are insufﬁ  cient for 
practical use. The performance of lymphoid organisation 
in the form of germinal centre (GC)-like lesions was 
evaluated in labial salivary gland biopsies taken at pSS 
diagnosis as a potential lymphoma-predicting biomarker.   
  Methods      Labial salivary gland tissue biopsies available 
from two Swedish pSS research cohorts (n=175) were 
re-evaluated by light microscopy in a blind study in 
order to identify GC-like structures as a sign of ectopic 
lymphoid tissue formation and organisation. A linkage 
study was performed with the Swedish Cancer Registry 
for lymphoma identiﬁ  cation. The risk of developing NHL 
in GC-positive patients in comparison with GC-negative 
patients was evaluated using Kaplan–Meier statistics and 
log-rank test. Associations between GC-like structures 
and clinical and/or laboratory disease markers were also 
determined using χ  2   or Fisher’s exact tests.   
  Results      At diagnosis, 25% of pSS patients had GC-like 
structures in their salivary glands. Seven of the 175 
patients studied (14% GC+ and 0.8% GC−) developed 
NHL during 1855 patient-years at risk, with a median 
onset of 7 years following the initial diagnostic salivary 
gland biopsy. Six of the seven patients had GC-like 
structures at diagnosis; the remaining patient was GC 
negative at the time of diagnosis (p=0.001).   
  Conclusions      The detection of GC-like structures by 
light microscopy in pSS diagnostic salivary biopsies is 
proposed as a highly predictive and easy-to-obtain marker 
for NHL development. This allows for risk stratiﬁ  cation of 
patients and the possibility to initiate preventive B-cell-
directed  therapy.      
  Primary Sjögren’s syndrome (pSS) is characterised by 
dryness of the mucous membranes throughout the 
body, and may affect various other internal organs 
by inﬂ  ammation or vasculitis to varying degrees. In 
most cases, pSS presents with a milder course of dis-
ease progression than other systemic rheumatic dis-
eases, for example, systemic lupus erythematosus.    1    
The increased risk of non-Hodgkin’s lymphoma 
(NHL) in pSS was ﬁ  rst described by Kassan   et al      2    in 
1978, who reported a 44-fold increased risk of NHL 
in pSS patients compared with that of the general 
population. Subsequent studies have determined 
the risk to be between six    3    and 20    4    times greater 
than within the general population, with 5–10% of 
all pSS patients expected to develop this potentially 
life-threatening complication. In fact, up to 18% of 
patients have been reported to develop NHL after 
a long follow-up,    5    with one study reporting that 
premature mortality in pSS patients is exclusively 
caused by the development of NHL.    6    
  Despite considerable efforts to identify risk fac-
tors or biomarkers for the development of NHL, 
neither which patients will develop NHL nor the 
expected time of the onset of lymphoma can be 
identiﬁ  ed  efﬁ   ciently. Some predictors have been 
repeatedly documented from large patient cohorts, 
namely hypocomplementaemia, persistent or recur-
rent salivary gland swelling, and cutaneous vasculi-
tis, palpable purpura and low C4    7       –       9    with HR of up 
to 9.5.    9    The combination of low C4 and palpable 
purpura at the time of initial presentation were pre-
viously proposed as markers of type I (high-risk) 
pSS.    7    A clear explanation as to why these factors 
should facilitate lymphoma development has not 
been elucidated. An association between ectopic 
germinal centre (GC) formation and the develop-
ment of lymphoma in pSS was originally proposed 
as early as 1999,    10    but a prospective study to deter-
mine the HR and predictive value of this phenom-
enon for lymphoma risk has not been performed. 
  In the present study, we aimed to determine 
whether GC formation in a lower labial salivary 
gland biopsy taken at the time of pSS diagnosis pre-
dicts the subsequent development of lymphoma at 
a later stage of the disease. Indeed, six out of seven 
pSS patients in our cohort who developed lym-
phoma had GC-like structures detectable by light 
microscopy at diagnosis; a median of 7 years (range 
2–12 years) before clinical lymphoma presentation. 
This ﬁ  nding may allow the clinician to identify the 
target population for repeated NHL screening and 
possibly the selection of candidates for preventive 
B-cell-directed biological treatment in pSS by utilis-
ing a simple routine diagnostic procedure.    11    
  PATIENTS  AND  METHODS 
    Patients and clinical information 
  One hundred and seventy-ﬁ  ve pSS patients were 
selected for the study out of 241 consecutive pSS 
patients from two Swedish centres with pSS 
research cohorts (Uppsala and Malmö University 
Hospitals) participating in a Nordic collaboration 
study on lymphoma and genetics. The study cohort 
comprised 161 (92%) female patients and 14 (8%) 
male patients, with an average age at diagnosis of 
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containing at least 50 mononuclear cells per 4 mm  2  . All avail-
able salivary gland tissue sections (n=175) were re-evaluated 
by one of the investigators (MVJ) at the Broegelmann Research 
Laboratory in Bergen, Norway. The re-assessment was per-
formed by light microscopy without previous knowledge of 
clinical data or the diagnosis from the initial biopsy evalua-
tion. Beyond the assessment of focal sialadenitis, the presence 
of ectopic GC-like structures was investigated. A biopsy was 
considered GC positive (GC+) in cases in which a well-circum-
scribed chronic inﬂ  ammatory cell inﬁ  ltrate consisting of at least 
50 mononuclear cells presented with features indicative of lym-
phoid organisation, such as a densely packed dark zone and a 
light zone within otherwise normal salivary gland epithelium 
(  ﬁ  gure 1C,D  ). Lymphoid organisation is not observed in con-
ventional focal inﬁ  ltrates (  ﬁ  gure 1A,B  ) and therefore these sec-
tions were classiﬁ  ed as GC negative (GC−). Focal inﬁ  ltrates and 
GC-like structures may occur within the same minor salivary 
gland,    14    and in such cases the section was characterised as GC+ 
(  ﬁ  gure 1C,D  ).   
  Presence  of  NHL 
  Registry linkage was performed on the entire study cohort 
(n=241) with the Swedish Cancer Registry    15    to 2007 using the 
unique national identiﬁ  cation number.    16    In patients in whom 
NHL was diagnosed, parafﬁ  n-embedded blocks were retrieved 
and consequently re-evaluated and lymphoma classiﬁ  ed accord-
ing to the WHO classiﬁ  cation    17    by a senior pathologist (GW).   
  Statistics 
  The risk of developing NHL in GC+ in comparison with GC− 
patients was ascertained using the Kaplan–Meier statistics/
log-rank test. Clinical manifestations of GC+ and GC− patients 
were compared by χ  2   statistics or Fisher’s exact test. Multivariate 
analyses could not be performed due to the limited number of 
lymphomas.   
51.3 years (±13.3). All included patients fulﬁ  lled the American 
European consensus criteria (AECC)    11    for pSS and were regularly 
followed, with registration of relevant clinical parameters such as 
salivary gland swelling, skin vasculitis, internal organ involvement 
and lymphadenopathy being chronicled. Likewise, laboratory 
variables were repeatedly studied, including autoantibody sta-
tus, blood status, immunoglobulin levels, complement function 
and T-cell subsets (with complement and T-cell subsets studied 
only in the Malmö cohort). With up to 25 years of individual fol-
low-ups at two separate units, the methods and reference ranges 
for the assessment of complement activity, autoantibody status, 
blood cells and cell subsets varied. The local reference levels at 
the time of analysis were thus used as cut-offs for determining 
seropositivity or abnormal levels. However, for serum autoanti-
bodies against Ro-60, Ro-52 (SSA) and La (SSB), a separate analy-
sis was performed using a bead-based multiplexed immune assay 
(xMap technology; Luminex, Austin, Texas, USA). Antinuclear 
antibody (ANA)  , anti-Ro/SSA, anti-La/SSB and rheumatoid fac-
tor (RF) autoantibodies were determined to be positive in 81%, 
64%, 39% and 55% of the patients, respectively. In addition, all 
patients were screened for organ involvement according to the 
recently established assessment instrument for disease activity in 
pSS (European League Against Rheumatism Sjögren’s syndrome 
disease activity index (ESSDAI)).    12      
    Salivary gland tissue re-evaluation and GC detection 
  One hundred and seventy-ﬁ  ve H&E stained parafﬁ  n-embedded 
minor salivary gland tissue biopsies taken at the time of pSS 
diagnosis were available from the 241 consecutive patients; 
the remaining patients either had no biopsy performed, or the 
biopsy material was lost or damaged and were thus excluded 
from the study. Tissue sections were previously evaluated for 
the presence of focal and periductal lymphocytic inﬁ  ltration    13    
according to the requirements of the AECC    11    (  ﬁ  gure 1A,B  ) with 
the focus score denoting the number of inﬂ  ammatory cell foci 
 Figure  1        Otherwise normal salivary gland tissue with periductal focal mononuclear cell inﬁ  ltrates (focal sialadenitis) but no germinal centre (GC)-like 
structures (GC− biopsy) (A and B) and salivary gland tissue with focal sialadenitis and GC-like structures (GC+ biopsy) (C and D).    
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(0.8%) among the 135 GC− patients (p=0.001;   table 1  ). The 
difference in lymphoma-free survival between GC+ and GC− 
patients is illustrated by the Kaplan–Meier curve showing a 
log-rank test of p=0.001 (  ﬁ  gure 3  ). The ﬁ  rst NHL in the study 
population was diagnosed 2 years and 4 months after the sali-
vary gland biopsy. The longest interval between GC+ salivary 
gland biopsy and the appearance of lymphoma was 12 years 
and 7 months. The positive predictive value for GC positivity 
was 16%, whereas the negative predictive value was 99%. For 
further patient and lymphoma details, please refer to supple-
mentary table S1 (available online only).     
  Previously established risk factors were also signiﬁ  cantly 
associated with lymphoma development in this cohort (  table 1  ). 
However, due to the retrospective nature of the study, with 
incomplete assessments of the other risk markers and together 
with the small number of lymphoma events, a direct compari-
son of risk estimates cannot be reliably performed.   
    Differences between patients with and without GC-like 
structures in their salivary gland biopsy 
  The differential occurrence of non-exocrine disease manifesta-
tions in GC+ and GC− patients was investigated using domains 
from the disease activity instrument ESSDAI    12    to determine the 
variables for comparison. In GC+ patients lymphadenopathy 
was present in 31%, but was observed only in 12% of GC− 
patients (p=0.006); haematological manifestations, mainly 
leucopenia and hypergammaglobulinaemia were also overrep-
resented among patients with GC-like structures. Furthermore, 
systemic disease affecting a higher number of organ systems 
was observed more frequently in GC+ patients in comparison 
with the GC− group (  table 2  ). Initial C4 levels were signiﬁ  cantly 
lower in GC+ patients, whereas C3 levels, the presence of 
cryoglobulins and CD4 T-cell counts did not differ signiﬁ  cantly 
between the two groups. As previously shown,    18    autoantibod-
ies such as anti-Ro/SSA, anti-La/SSB, ANA and RF were more 
frequently detected among GC+ than GC− patients.       
    Follow-up and observation time 
  The observation time for the present study was deﬁ  ned as the 
time from salivary gland biopsy to lymphoma diagnosis, death, 
or end of clinical follow-up, whichever occurred ﬁ  rst.     
  RESULTS 
    Salivary gland tissue re-evaluation and GC status establishment 
  Of the 175 salivary gland tissue biopsies examined, focal sialad-
enitis (  ﬁ  gure 1  ) with a focus score of 1 or greater was detected in 
136 (78%) patients. The remaining 39 patients were categorised 
as having a ‘negative’ biopsy,    11        13    and fulﬁ  lled pSS classiﬁ  cation 
criteria due to the presence of autoantibodies against Ro/SSA 
and/or La/SSB. Among the 136 patients with focal sialadenitis, 43 
(32%) showed GC-like structures in the diagnostic salivary gland 
biopsy. GC-like structures may only be found in the presence of 
focal lymphocyte accumulation and consequently only when 
autoimmune sialadenitis is present. When considering the whole 
cohort, 25% of the 175 patients had GC-like structures (  ﬁ  gure 2  ).       
  Follow-up  times 
  The average follow-up time of all patients was 10.6 years 
(range 1 month to 25 years), with a mean of 11.6 years in GC+ 
patients and 10.3 years in GC− patients, p=0.23. The median 
time between the diagnosis of pSS and performing a salivary 
gland biopsy was 2 weeks (IQR of 0–19 weeks; total range of 
−227 to 624 weeks), whereas the time between salivary gland 
biopsy and NHL diagnosis was on average 7 years 2 months 
(range 2 years 4 months to 12 years 7 months).   
    Risk of lymphoma development in GC+ and GC− patients 
  Registry linkage conﬁ  rmed that seven of the 175 pSS patients 
had developed NHL. Six of seven patients with lymphoma had 
GC-like structures in their salivary glands at pSS diagnosis, per-
formed a median of 7 years before the occurrence of lymphoma. 
Therefore, among the 43 patients with GC-like structures, six 
patients (14%) developed lymphomas in contrast to one patient 
 Figure  2        Patient distribution after re-evaluation of the diagnostic salivary gland biopsy and distribution of lymphoma events.       
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such as upregulated interferon alpha (IFNα) signature    21        22    and 
increased B cell activating factor of the TNF family of ligands 
(BAFF)   levels    14        23    may exert their effects in multiple sites with 
ongoing antigenic stimulation. The reduced levels of memory B 
cells in pSS peripheral blood,    24        25    possibly due to migration into 
inﬂ  amed tissue,    26    also supports a process expanding beyond the 
salivary glands. Whether our lymphoma patients expressed ante-
cedent GC-like structures in the organs where the lymphoma 
evolved, or if lymphoma inﬁ  ltration of the salivary glands was 
present at the time point of lymphoma detection in these other 
organs, is not known. Gasparotto   et al      27    published a single case 
of pSS in which salivary gland swelling and parotid lymphop-
roliferation was followed by pulmonary lymphoma, showing 
partly the same B-cell clone in both sites. This is suggestive of a 
contribution of the local environment in the ﬁ  nal transition from 
non-neoplastic to malignant B-cell proliferation. 
  In our patient material, the single GC− lymphoma patient 
diagnosed with mucosa-associated lymphoid tissue   lymphoma 
of a tear gland was ascertained to have borderline small foci in 
the minor salivary gland biopsy. In addition to other recognised 
risk factors for the development of lymphoma, the patient also 
lacked autoantibodies against Ro/SSA and La/SSB. 
  Treatment options beyond supportive, symptomatic and ﬂ  uid 
replacement measures in pSS are scarce. However, expensive 
B-cell-directed therapies have been proposed as a potential pre-
ventive measure for the development of lymphoma. Established 
biomarkers and guidelines for identifying which patients to treat 
are urgently needed. We here propose the presence of GC-like 
structures as a possible marker to identify patients at a higher 
risk of developing NHL. 
  Our ﬁ  ndings revealed only a limited association of GC for-
mation with other well-established markers of lymphoma 
development. Nonetheless, low C4 levels, leucopenia and 
hypergammaglobulinaemia were all associated with lymphoid 
organisation. A trend was observed for C3 and CD4 T-cell lev-
els to be lower in GC+ patients; however, this did not reach 
statistical signiﬁ  cance, possibly due to lack of power or maybe 
  DISCUSSION 
  The 20-fold increased risk of NHL with premature mortality as 
a consequence is one of the main problems in the clinical man-
agement of pSS. The results of the present study propose a new, 
potent and easy-to-use tool for risk assessment of developing NHL 
and possibly treatment tailoring. The labial salivary gland biopsy 
is performed as part of the diagnostic process, constituting one 
of two items within the AECC criteria set required for classiﬁ  ca-
tion.    11    We show here that six of the seven pSS patients with NHL 
had GC-like structures in the initial minor salivary gland biopsy. 
  GC-like structures were apparent in 25% of the patients in 
the study cohort, with NHL expected to occur in approximately 
10% of all pSS patients during their lifetime. While GC are rec-
ognised as important loci for the maturation of B cells and the 
generation of B-cell lymphomas,    19        20    GC positivity alone seems 
not sufﬁ  cient as a sole contributor and with additional factors 
required for the evolvement of NHL. Furthermore, we only 
examined GC-like structures in minor salivary glands, yet the 
lymphomas in our patient cohort presented in other organs in 
ﬁ  ve out of seven cases (see   ﬁ  gure 3   and supplementary table S1, 
available online only). Based on our results, one might specu-
late that the formation of GC-like structures is a widespread or 
multi-local phenomenon in pSS patients prone to lymphoprolif-
eration. Systemic ﬁ  ndings of pSS-promoting B-cell proliferation 
 Figure  3        Kaplan–Meier curve showing lymphoma-free survival in germinal centre (GC)+ and GC− patients with individual lymphoma information 
added. DLBC, diffuse large B cell lymphoma; NHL, non-Hodgkin’s lymphoma.          
  Table  1         Association of proposed risk factors with lymphoma 
occurrence in the pSS study cohort   
   Lymphoma   No  lymphoma   p  Value* 
GC positivity† 6 (86%) 37 (22%) 0.001
CD4 T lymphocytopaenia†‡ 4 (80%) 15 (14%) 0.003
C3, lowest quartile† 3 (50%) 36 (24%) 0.17
C4, lowest quartile† 4 (67%) 29 (25%) 0.043
Cryoglobulinaemia† 2 (33%) 13 (16%) 0.261
   *Fisher’s  exact  test. 
  †Values represent n/% of available. 
  ‡CD4 T lymphocytopaenia: either CD4 T cells less than 300 cells/ml or CD4 T cells less 
than 30% of total lymphocyte count or low CD4/CD8 ratio: less than 0.8. 
  GC, germinal centre; pSS, primary Sjögren’s syndrome.     
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  In conclusion, we present a new marker of lymphoma devel-
opment in pSS patients present in 86% of the patients presenting 
with NHL later on. This marker is detectable already at diag-
nosis in labial salivary gland biopsies by routine light micros-
copy of H&E sections. Although this predictor does not allow 
the precise determination of the time of onset of lymphoma, 
it certainly aids stratiﬁ  cation to identify high-risk patients who 
should be closely monitored by lymphoma screening, close fol-
low-up and possibly advanced interventions for the treatment of 
both the frequently associated systemic disease manifestations 
and ultimately for the prevention of lymphoma. 
  We propose that an assessment of lymphoid organisation in 
labial salivary glands is routinely performed by the pathologist 
along with the histopathological focus score evaluation as fur-
ther material or staining is not required. We also encourage rheu-
matologists to include the minor salivary gland biopsy in the 
routine work-up during the diagnosis of pSS, even if it formally 
would not be necessary in Ro/SSA and/or La/SSB-seropositive 
cases. The value of ectopic GC-like structures can thus be evalu-
ated prospectively.     
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